Datar Cancer Genetics Receives Landmark FDA Approval for CellDx-Tissue
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
CHICAGO — March 11, 2026 Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence...
